Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure

NCT03255551 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-08-21

No results posted yet for this study

Summary

Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension

Conditions

Interventions

DRUG

Amosartan

amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2015-06-30
Completion
2015-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03255551 on ClinicalTrials.gov